Letermovir Conversion for Cytomegalovirus Prophylaxis in Solid Organ Transplant
LTV was effective and well-tolerated for primary CMV prophylaxis in an extra-renal transplant population and may be a safe alternative in patients experiencing sustained hematologic toxicities with (val)ganciclovir across all transplant groups.
Authors
- A. Osama Gaber (ORCID: https://orcid.org/0000-0002-0743-4974)
- A. Rogers (ORCID: https://orcid.org/0000-0003-0325-4535)
- R. Mark Ghobrial (ORCID: https://orcid.org/0000-0001-6077-9595)
- Allison N. Yun
- Suneri J. Amin (ORCID: https://orcid.org/0000-0001-8586-5211)
- Masayuki Nigo (ORCID: https://orcid.org/0000-0003-4898-1808)
Institutions
- Methodist Hospital (US)
Publication Details
- Journal
- Clinical Transplantation
- Published
- 2025-10-25
- DOI
- https://doi.org/10.1111/ctr.70366
- Primary Topic
- Cytomegalovirus and herpesvirus research
- Type
- article
- Field-Weighted Citation Impact
- 0.00